BRAF and non-small cell lung carcinoma: NSCLC patients harboring non-V600 BRAF alterations constitute a considerable and underestimated population characterized by peculiar genomic landscape and poor prognosis compared to BRAF wild-type patients, warranting larger and deeper studies aiming to identify potential tailored therapies.